Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 13 2013 Tradename Applicant Generic Name Patent Expiration ZAVESCA Actelion Pharms Ltd miglustat May 13, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics What are the Top-selling Drugs? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 7 2013 Tradename Applicant Generic Name Patent Expiration GEMZAR Lilly gemcitabine hydrochloride May 7, 2013 HUMALOG Lilly insulin lispro recombinant May 7, 2013 HUMALOG KWIKPEN Lilly insulin lispro recombinant May 7, 2013 HUMALOG MIX 50/50 Lilly insulin lispro protamine recombinant; insulin lispro recombinant May 7, 2013 HUMALOG MIX 50/50 KWIKPEN Lilly insulin lispro protamine recombinant; insulin lispro recombinant May 7, 2013 HUMALOG MIX 75/25 Lilly insulin lispro protamine recombinant; insulin lispro recombinant May 7, 2013 HUMALOG MIX 75/25 KWIKPEN Lilly insulin lispro protamine recombinant; insulin lispro recombinant May 7, 2013 HUMALOG PEN Lilly insulin lispro recombinant May 7, 2013 PREVACID Takeda Pharms Usa lansoprazole May 7, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics What are the Top-selling Drugs? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 14 2013 Tradename Applicant Generic Name Patent Expiration DEPOCYT Pacira Pharms Inc cytarabine May 14, 2013 ZOMIG Astrazeneca zolmitriptan May 14, 2013 ZOMIG Ipr zolmitriptan May 14, 2013 ZOMIG-ZMT Astrazeneca zolmitriptan May 14, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics What are the Top-selling Drugs? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 18 2013 Tradename Applicant Generic Name Patent Expiration OSMOPREP Salix Pharms sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate May 18, 2013 VISICOL Salix Pharms sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate May 18, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics What are the Top-selling Drugs? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Singapore's biomedical science sector development strategy: Is it sustainable?

Go to paper

ABSTRACT: This paper outlines the strategic efforts undertaken by Singapore to establish its national capability in the biomedical science sector, reviews the commercial base as a result of these efforts and compares Singapore's approach with the UK and US development models, discusses the challenges that Singapore faces and raises some questions on the long-term sustainability of the sector...

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 30 2013 Tradename Applicant Generic Name Patent Expiration ALVESCO Takeda Gmbh ciclesonide Apr 30, 2013 CEDAX Pernix Therap ceftibuten dihydrate Apr 30, 2013 ZETONNA Takeda Gmbh ciclesonide Apr 30, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics What are the Top-selling Drugs? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

After months of development, BiologicPatentWatch.com is live.

Building on the framework of DrugPatentWatch, BiologicPatentWatch provides comprehensive details on FDA approved biologic drugs, developers and patents. The integrated databases allow both freeform searching and dynamic browsing, making it easy to find information on drug patents both in the US and internationally, Orphan Drug Status, trends in patent expirations and more …

 BiologicPatentWatch concentrates deep knowledge on biologic drugs from more than 60 biotechnology companies, including more than 2,800 active and expired US patents and 41,000 international patents spanning 91 countries and regional patent offices.

BiologicPatentWatch complements DrugPatentWatch’s focus on small molecule drugs, and provides comprehensive information on:

• monoclonal antibodies
• cytokines, growth factors, enzymes, immunomodulators; and thrombolytics
• proteins intended for therapeutic use that are extracted from animals or microorganisms, including recombinant versions of these products (except clotting factors)
• other non-vaccine therapeutic immunotherapies

Check out the free biotechnology industry infographics and database preview, or sign up for a free trial today!

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below.

In an unanimous decision in Bowman v. Monsanto, argued February 19, 2013 and decided May 13, 2013, the U.S. Supreme Court explicitly confirms that the exhaustion doctrine does not extend to progeny of so-called self-replicating technologies.

We provided a summary of the oral argument here in the blog, and a longer  look at the case in a recent issue of the Journal for Commercial Biotechnology, here, anticipating that the primary point of interest in the case for the U.S. Supreme Court was the opportunity to address the intersection of the exhaustion doctrine and self-replicating inventions.

The idea that the case was all about a new asserted exception from patent rights for digital and GM technologies was signaled by statements of the Justices at Oral Argument and so was not particularly insightful.  Now this has been borne out by the Opinion of the U.S. Supreme Court, delivered this morning by Justin Kagan:

[T]he exhaustion doctrine does not enable Bowman to make additional patented soybeans without Monsanto’s permission (either express or implied). And that is precisely what Bowman did. He took the soybeans he purchased home; planted them in his fields at the time he thought best; applied glyphosate to kill weeds (as well as any soy plants lacking the Roundup Ready trait); and finally harvested more (many more) beans than he started with. That is how “to ‘make’ a new product,” to use Bowman’s words, when the original product is a seed. Brief for Petitioner 37; see Webster’s Third New International Dictionary 1363 (1961) (“make” means “cause to exist, occur, or appear,” or more specifically, “plant and raise (a crop)”). Because Bowman thus reproduced Monsanto’s pa tented invention, the exhaustion doctrine does not protect him. Were the matter otherwise, Monsanto’s patent would provide scant benefit.

In sum, Petitioner Vernon Hugh Bowman does not pass, go, collect $200 or otherwise avoid licensing fees by purchasing patented GM seeds outside of his ongoing Technology Agreement with the inventor and Respondent, Monsanto Company.

Just like death and taxes, Bowman has to pay for the advanced technologies and other agricultural inputs that he wants to use, including GM seeds that make his job easier, improve yields and contribute to the success of his farm.  And as noted previously, both Monsanto and U.S. Government attorneys have stated that this case does not affect farmers who do not intentionally plant GM seeds without payment of royalties.

Susan K. Finston is President of Finston Consulting LLC, and, together with biotechnology pioneer Ananda Chakrabarty, is co-founder of Amrita Therapeutics Ltd., an emerging biopharmaceutical company based in India with cancer peptide drugs entering in vivoresearch. She is currently preparing to launch her first Crowd Funding campaign for Amrita Therapeutics first-ever therapeutic oncology medical device. For more information see AmritaTherapeutics.com or FinstonConsulting.com.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Advertise here

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for April 29 2013 Tradename Applicant Generic Name Patent Expiration HYTRIN Abbott terazosin hydrochloride Apr 29, 2013 *Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details. DrugPatentWatch Infographics How Many Drug Patents Will Expire in the Coming Months? More infographics » DrugPatentWatch Serves Your Competitive Intelligence Needs Subscribers have access to valuable datasets, including: Patent litigation Clinical trial information International patent families International patent priority and PCT information Patent maintenance Full-text patent downloads Paragraph IV challenges Tentative approvals Drug Master Files Dynamic search capabilities with data export More… See the Database Preview and Plan Comparison. Contact Us with any questions.

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch

Drug Patent Expirations for May 2013

Journal of Commercial Biotechnology | BiotechBlog | Books | Publishing opportunities | DrugPatentWatch